# Pediatric Hepatoblastoma: From Developmental Molecular Mechanisms to Innovative Therapeutic Strategies

## TL;DR

Pediatric hepatoblastoma is a liver cancer linked to developmental pathways and immune evasion, requiring new strategies to improve treatment and outcomes.

## Contribution

The paper integrates molecular biology with clinical insights to propose precision medicine approaches for hepatoblastoma.

## Key findings

- Hepatoblastoma involves aberrant Wnt/β-catenin, Hippo–YAP, IGF, and mTOR signaling pathways.
- Tumor heterogeneity is driven by stem-like cells and an immune-cold microenvironment.
- Biological stratification and multi-omics approaches may refine risk assessment and treatment adaptation.

## Abstract

Pediatric hepatoblastoma is a developmentally driven liver malignancy characterized by aberrant activation of fetal signaling pathways and persistence of stem-like tumor cell populations. Tumor heterogeneity is reinforced by hypoxia, angiogenesis, and an immune-cold microenvironment, contributing to therapeutic resistance and relapse. Integrating molecular biology with clinical and surgical decision-making may enable personalized treatment strategies, rational therapy de-escalation, and improved long-term outcomes. Despite advances in multimodal therapy, current risk stratification still relies predominantly on clinical and imaging-based parameters, with limited incorporation of biological data. A better understanding of tumor biology and its integration into routine practice may help refine patient selection, optimize treatment intensity, and reduce long-term toxicity in survivors.

Background/Objectives: Hepatoblastoma, the most common pediatric primary liver cancer, is no longer regarded as a conventional malignancy but rather as a tumor emerging from disrupted hepatic developmental processes. Although improvements in chemotherapy, surgical techniques, and liver transplantation have markedly enhanced survival, therapeutic decision-making is still primarily guided by anatomical criteria and insufficiently reflects the biological heterogeneity that contributes to variable treatment response and disease recurrence. This narrative review integrates recent advances in molecular biology, tumor stemness, microenvironmental interactions, and translational research models in pediatric hepatoblastoma. We critically examine how developmental signaling pathways, cellular plasticity, and immune–vascular context shape tumor behavior and therapeutic vulnerability, with a focus on emerging targeted, anti-angiogenic, immune, and epigenetic strategies. Results: Hepatoblastoma is characterized by aberrant activation of key developmental pathways, including Wnt/β-catenin, Hippo–YAP, IGF, and mTOR signaling, which cooperate to sustain proliferation, stem-like phenotypes, and treatment resistance. Tumor heterogeneity is further reinforced by cancer stem cell populations and a predominantly immune-cold microenvironment. While innovative therapeutic approaches show promise, their clinical impact has been limited by biological complexity and insufficient integration into current treatment algorithms. Liquid biopsy biomarkers, advanced translational models, and multi-omics approaches offer new opportunities for biologically informed risk stratification and therapy adaptation. Conclusions: Future progress in pediatric hepatoblastoma will require a paradigm shift from purely clinicopathological management toward an integrated molecular and surgical framework. Incorporating biological stratification into therapeutic decision-making may enable personalized treatment, rational therapy de-escalation, and improved outcomes for high-risk disease. This review highlights the foundations and future directions for precision medicine in hepatoblastoma.